HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trialAntonio Llombart‐Cussac, Aleix Prat, Javier Cortés et al.|The Lancet Oncology|2017Cited by 340
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trialAleix Prat, Joaquín Gavilá, Tomás Pascual et al.|The Lancet Oncology|2019Cited by 199
Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based TherapeuticsRobert G. Petit, Elena Sánchez‐López, Amanda Cano et al.|International Journal of Molecular Sciences|2021Cited by 150
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluationAleix Prat, PierFranco Conte, Valentina Guarneri et al.|The Lancet Oncology|2020Cited by 75
Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.Kevin Kalinsky, Seth A. Wander, Giampaolo Bianchini et al.|Journal of Clinical Oncology|2024Cited by 75